Rhythm Pharmaceuticals Inc.
NASDAQ:RYTM 3:59:50 PM EDT
| Market Cap (Intraday) | 1.04B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $21.07 |
| 50-Day MA | $25.34 |
| 200-Day MA | $25.48 |
Rhythm Pharmaceuticals, Inc. Stock, NASDAQ:RYTM
222 Berkeley Street, 12th floor, Boston, Massachusetts 02116
United States of America
Phone: +1.857.264.4280
Number of Employees: 70
Description
Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.